Major study probes potential cancer link to popular diabetes drug
NCT ID NCT05663515
Summary
This study aims to find out if a diabetes medication called exenatide increases the risk of pancreatic cancer compared to other diabetes drugs. Researchers will analyze the health records of 24,000 type 2 diabetes patients across Europe from 2006 to 2023. The study is observational, meaning it looks back at existing data to check for safety signals, and does not involve giving patients any new treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGCopenhagen, Denmark
-
Research Site
RECRUITINGHelsinki, Finland
-
Research Site
RECRUITINGParis, France
-
Research Site
RECRUITINGBergen, Norway
-
Research Site
RECRUITINGBarcelona, Spain
-
Research Site
RECRUITINGVänersborg, Sweden
-
Research Site
RECRUITINGEdinburgh, United Kingdom
-
Research Site
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.